AR106471A1 - ANTIBODY THAT NEUTRALIZES THE HUMAN SYNTHETIC RESPIRATORY VIRUS - Google Patents
ANTIBODY THAT NEUTRALIZES THE HUMAN SYNTHETIC RESPIRATORY VIRUSInfo
- Publication number
- AR106471A1 AR106471A1 ARP160103254A ARP160103254A AR106471A1 AR 106471 A1 AR106471 A1 AR 106471A1 AR P160103254 A ARP160103254 A AR P160103254A AR P160103254 A ARP160103254 A AR P160103254A AR 106471 A1 AR106471 A1 AR 106471A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- variable region
- amino acid
- acid sequence
- antibody
- Prior art date
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud se refiere a anticuerpos monoclonales que tienen altos títulos neutralizantes anti-VRS. La solicitud proporciona además ácidos nucleicos aislados que codifican los anticuerpos de la solicitud y células huésped transformadas con los mismos. La solicitud proporciona aún además métodos de diagnóstico, profilácticos y terapéuticos que emplean los anticuerpos y ácidos nucleicos de la solicitud, particularmente como un agente de inmunoterapia pasiva en lactantes y ancianos. Reivindicación 1: Un anticuerpo aislado o fragmento de unión al antígeno del mismo que se une a la proteína F del VRS humano, en el que el anticuerpo o fragmento de unión al antígeno comprende una región variable de la cadena pesada CDR1 que comprende la secuencia de aminoácidos de SEQ ID Nº 1, una región variable de la cadena pesada CDR2 que comprende la secuencia de aminoácidos de SEQ ID Nº 2, una región variable de la cadena pesada CDR3 que comprende la secuencia de aminoácidos de SEQ ID Nº 3, una región variable de la cadena ligera CDR1 que comprende la secuencia de aminoácidos de SEQ ID Nº 4, una región variable de la cadena ligera CDR2 que comprende la secuencia de aminoácidos de SEQ ID Nº 5, y una región variable de la cadena ligera CDR3 que comprende la secuencia de aminoácidos de SEQ ID Nº 6.The present application relates to monoclonal antibodies that have high anti-RSV neutralizing titres. The application further provides isolated nucleic acids encoding the antibodies of the request and host cells transformed therewith. The application further provides diagnostic, prophylactic and therapeutic methods that employ the antibodies and nucleic acids of the application, particularly as a passive immunotherapy agent in infants and the elderly. Claim 1: An isolated antibody or antigen binding fragment thereof that binds to the human RSV F protein, wherein the antibody or antigen binding fragment comprises a variable region of the CDR1 heavy chain comprising the sequence of amino acids of SEQ ID No. 1, a variable region of the CDR2 heavy chain comprising the amino acid sequence of SEQ ID No. 2, a variable region of the CDR3 heavy chain comprising the amino acid sequence of SEQ ID No. 3, a variable region of the CDR1 light chain comprising the amino acid sequence of SEQ ID No. 4, a variable region of the CDR2 light chain comprising the amino acid sequence of SEQ ID No. 5, and a variable region of the CDR3 light chain comprising the sequence of amino acids of SEQ ID No. 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562247841P | 2015-10-29 | 2015-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106471A1 true AR106471A1 (en) | 2018-01-17 |
Family
ID=61159870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103254A AR106471A1 (en) | 2015-10-29 | 2016-10-25 | ANTIBODY THAT NEUTRALIZES THE HUMAN SYNTHETIC RESPIRATORY VIRUS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR106471A1 (en) |
| EC (1) | ECSP18039827A (en) |
-
2016
- 2016-10-25 AR ARP160103254A patent/AR106471A1/en unknown
-
2018
- 2018-05-24 EC ECIEPI201839827A patent/ECSP18039827A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP18039827A (en) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181270A1 (en) | ANTIBODY THAT NEUTRALIZES THE HUMAN SYNCITIAL RESPIRATORY VIRUS | |
| CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
| AR109715A1 (en) | ANTI-CD27 ANTIBODIES | |
| AR106991A1 (en) | NEUTRALIZING ANTIBODIES OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| HRP20170568T1 (en) | Anti-ox40 antibodies and methods of using the same | |
| BR112019008010A2 (en) | isolated monoclonal antibody or immunologically active fragment thereof, isolated bispecific monoclonal antibody, pharmaceutical composition, method for treating a disease in a human subject in need thereof, fusion protein, cd47 gene encoded immunodominant epitope, and biological molecule | |
| ES2776179T3 (en) | Antibodies directed against surface determinants of S. aureus | |
| EA201891435A1 (en) | HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47 | |
| MX2021010519A (en) | Prefusion rsv f proteins and their use. | |
| ES2670621T3 (en) | Antibodies that bind to OX40 and its uses | |
| PE20221580A1 (en) | THERAPEUTIC ANTIBODIES AND THEIR USES | |
| RU2014101707A (en) | ANTI-Axl ANTIBODIES AND THEIR APPLICATION | |
| AR105026A1 (en) | ANTIBODIES MATURED BY AFFINITY AND HUMANIZED FOR FcRH5 AND METHODS FOR USE | |
| PE20181054A1 (en) | HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE | |
| JP2017524339A5 (en) | ||
| AR101875A1 (en) | ANTIGENS, BI-SPECIFIC UNION PROTEIN OF THE ANTI-CGRP RECEIVER / PAC1 RECEIVER AND USES OF THE SAME | |
| MX2014000749A (en) | Neutralizing anti-influenza a virus antibodies and uses thereof. | |
| SG10201806025TA (en) | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen | |
| PE20161311A1 (en) | SPECIFIC ANTIBODIES OF THE INSULIN-SIMILAR GROWTH FACTOR 1 RECEPTOR AND USES OF THE SAME. | |
| PE20161221A1 (en) | IL-21 ANTIBODIES | |
| RU2016107814A (en) | NEW ANTIBODY TO HUMAN TSLP RECEPTOR | |
| PE20161245A1 (en) | SPECIFIC ANTIBODIES OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND USES OF THEM | |
| RU2017113732A (en) | AN ANTIBODY THAT HAS THE ABILITY TO NEUTRALIZE AN ACTIVITY SUBSTANCE, AN ALTERNATIVE FUNCTION OF COLLECTION FACTOR VIII (FVIII) | |
| AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
| PE20141683A1 (en) | SPECIFIC MONOCLONAL ANTIBODIES FOR RESPIRATORY SYNCITIAL VIRUS (RSV) M2-1 ANTIGEN |